Time course analysis and modulating effects of established brain tumor on active-specific immunotherapy.

  title={Time course analysis and modulating effects of established brain tumor on active-specific immunotherapy.},
  author={Y. Liu and K. Ng and K. Lillehei},
  journal={Neurosurgical focus},
  volume={9 6},
OBJECT There have been numerous attempts to establish an effective immunotherapy for the treatment of brain tumors. To date, reliable methods to manipulate the immune system for promoting brain tumor regression have been disappointing. Generation of active immune responses in most of these studies was only possible in the absence of viable tumor cells, suggesting that immunotherapy can only be used as preventive therapy. In few studies the investigators have demonstrated success in using… Expand
Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma.
Novel strategies to generate an anti-glioma immune response through use of dendritic cell vaccination, directed cytokine delivery, gene-based immunotherapy, and reversal of tumor-induced immunosuppression are promising and carry the potential of overcoming the resistance of gliomas to immunotherapeutic manipulation. Expand
TGF-β2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors
The hypothesis that local administration of antisense TGF-β2 ODNs combined with systemic vaccination can increase efficacy of immunotherapy and is a novel, potentially clinically applicable, strategy for high-grade glioma treatment is supported. Expand
Immune and viral therapies for malignant primary brain tumors
Preclinical and clinical studies utilizing biological therapeutic approaches for treating brain tumors have the potential to augment the current standard of care to provide potential curative therapies and engineering of viruses for oncolytic targeting and destruction of malignant tumors within the brain. Expand
Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas
The results suggest that MSC infiltration and unregulated tumor growth in response to vaccination is T cell-dependent; is not unique to the T9 glioma; and can be recapitulated with an alternate immunization approach. Expand
Preclinical Changes in Immunoreactivity and Cellular Architecture during the Progressive Development of Intracranial Neoplasms and an Immunotherapeutic Schedule with a Novel Biological Response Modifier, the T11TS / S-LFA3.
Among neoplasms, brain tumors are particularly " difficult to treat" because of the partial immune privileged status of the brain and the presence of the blood brain barrier (Selmaj, 1996). ManyExpand
Intracerebral Administration of Heat-Inactivated Staphylococcus Epidermidis Enhances Oncolysis and Prolongs Survival in a 9L Orthotopic Gliosarcoma Model
A novel approach for combatting malignant glioma using inactivated staphylococci as potent immunomodulators using HISE-immunostimulation in an experimentalglioma model is described. Expand
Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells
The emphasis is on the novel strategy of active specific immunotherapy using dendritic cells as antigen-presenting cells, especially its theoretical concepts and advantages, specific requirements, critical issues, pre-clinical and early clinical experience. Expand
T11TS/S-LFA3 induces apoptosis of the brain tumor cells: a new approach to characterise the apoptosis associated genetic changes by arbitrarily primed-PCR.
The results clearly establish the apoptogenic role of T11TS/S-LFA3 and along with the detection of cancer associated genomic instability, AP-PCR analysis is useful for the detectionof DNA level fragmentation, a unique feature of apoptosis. Expand
Immunotherapeutic effects of T11TS/S-LFA3 against nitrosocompound mediated neural genotoxicity.
The present study indicated that a transmembrane glycopeptide of sheep red blood cell (SRBC), known as S-LFA3 or T11 target structure (T11TS) applied to nitrosocompound induced animals manifesting a full grown intracranial malignancy can revert back tumor-bearing condition to the normal physiological state. Expand


Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy.
  • H. Fakhrai, O. Dorigo, +5 authors R. Sobol
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1996
Results indicate that inhibition of TGF-beta expression significantly enhances tumor-cell immunogenicity and supports future clinical evaluation of T GF-beta antisense gene therapy for TGF -beta-expressing tumors. Expand
Interleukin-12-based immunotherapy against rat 9L glioma.
Continuous administration of the lymphokine IL-12, in the presence of irradiated tumor cells for antigen presentation, circumvents the need for gene transfection for generating tumor cell vaccines. Expand
Immunobiology of primary intracranial tumors. Part 7: Active immunization of patients with anaplastic human glioma cells: a pilot study.
Twenty patients with malignant gliomas were selected for active immunization within 4 weeks following surgery, and Serial studies of general immune competence showed no alterations from those previously described with non-immunized patients. Expand
Immunotherapy of brain tumors.
Among these factors, TGF-beta 2 and PGE2 are of particular interest since they may explain the generally depressed cellular immune response observed in patients with malignant gliomas. Expand
Immunity to Transplantable Nitrosourea‐Induced Neurogenic Tumors: II. Immunoprophylaxis of Tumors of the Brain
T9 cells are moderately immunogenic, an effective method of immunization of CDF rats against ID transplanted T9 cells is 106 T 9 cells with 0.14 mg C. parvum, and spleen cells of highly immunized rats are cytotoxic to T9 tumor cells. Expand
The immune mechanisms of the central nervous system, particularly in relation to transplantable tumors and homografts, have not been studied extensively and the results of currentatment of malignant gliomas, and the opportunities to study the immune mechanism of thecentral nervous system should encourage investigation of the effects of immunization on transplantable cerebral glioma. Expand
Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment.
  • P. Siesjö, E. Visse, H. Sjögren
  • Medicine
  • Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy
  • 1996
The overall results show that therapeutic immunizations can indeed be effective against an established and growing intracerebral tumor and demonstrates that effective immunizations against a weakly immunogenic brain tumor can be achieved by different adjuvant concepts. Expand
Immunity to Transplantable Nitrosourea‐induced Neurogenic Tumors: I. Potentiation of Tumor Immunity with Corynebacterium parvum
Tumor immunity was specific, since growth of an unrelated tumor was unaffected, and it is suggested that local immunological reactivity to C. parvum in the immunizing tumor promotes development of specific tumor immunity. Expand
Generation of cytotoxic immune responses against a rat glioma by in vivo priming and secondary in vitro stimulation with tumor cells.
The results demonstrated that brain tumor-specific CTL could be produced by priming in vivo followed by secondary stimulation with brain tumor cells in vitro, and demonstrated that RT2 and 9L share antigens that both induce and serve as target structures for specific cytotoxic cells. Expand
Data suggest that the suppressor factor may be an isoantibody elicited by the tumor that also binds to receptors on the lymphocyte membrane, and in addition to specifically blocking cell-mediated tumor immunity, enhancing sera may broadly depress host immunocompetence. Expand